Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma

(2016) Xuemei Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914

(2015) Eva M. Huber et al.   STRUCTURE

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib

(2014) A Ray et al.   LEUKEMIA

Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine

(2014) Rimda Wanchoo et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1128–350 triggers MM cell death via c-Jun upregulation

(2013) Fengjuan Fan et al.   CANCER LETTERS

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

(2013) A Thakurta et al.   LEUKEMIA

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4

(2012) Kwang Min Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

(2012) P. G. Richardson et al.   BLOOD

Addiction to c-MYC in multiple myeloma

(2012) T. Holien et al.   BLOOD

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

(2012) Ling-Hua Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

(2012) Kenneth C. Anderson   JOURNAL OF CLINICAL ONCOLOGY

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

(2009) D. Chauhan et al.   BLOOD

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Targeting the UPS as therapy in multiple myeloma

(2008) Dharminder Chauhan et al.   BMC BIOCHEMISTRY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE